Indolylarylsulfones bearing natural and unnatural amino acids. discovery of potent inhibitors of hiv-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie b4 virus

Journal of Medicinal Chemistry

Volumn 52, Issue 7, 2009, Pages 1922-1934

  Piscitelli, Francesco ^a   Coluccia, Antonio ^b   Brancale, Andrea ^b   La Regina, Giuseppe ^a   Sansone, Anna ^a   Giordano, Cesare ^a   Balzarini, Jan ^c   Maga, Giovanni ^d   Zanoli, Samantha ^d   Samuele, Alberta ^d   Cirilli, Roberto ^e   La Torre, Francesco ^e   Lavecchia, Antonio ^f   Novellino, Ettore ^f   Silvestri, Romano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d CNR   (Italy)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(3,5 DIMETHYLPHENYL)SULFONYL] 5 NITRO N (2 SULFAMOYLETHYL) 1H INDOLE 2 CARBOXAMIDE; 5 BROMO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] N (2 SULFAMOYLETHYL) 1H INDOLE 2 CARBOXAMIDE; 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 4 FLUORO N (1 SULFAMOYLPROPAN 2 YL) 1H INDOLE 2 CARBOXAMIDE; 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 4 FLUORO N (2 SULFAMOYLETHYL) 1H INDOLE 2 CARBOXAMIDE; 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 5 NITRO N (1 SULFAMOYLPROPAN 2 YL) 1H INDOLE 2 CARBOXAMIDE; 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] N (1 SULFAMOYLPROPAN 2 YL) 1H INDOLE 2 CARBOXAMIDE; 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] N (1 SULFAMOYLPROPAN 3 YL) 1H INDOLE 2 CARBOXAMIDE; 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] N (2 SULFAMOYLETHYL) 1H INDOLE 2 CARBOXAMIDE; EFAVIRENZ; INDOLYLARYLSULFONE DERIVATIVE; N (1 AMINO 1 OXOPROPAN 2 YL) 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 5 NITRO 1H INDOLE 2 CARBOXAMIDE; N (1 AMINO 1 OXOPROPAN 2 YL) 5 BROMO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 1H INDOLE 2 CARBOXAMIDE; N (1 AMINO 1 OXOPROPAN 2 YL) 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 1H INDOLE 2 CARBOXAMIDE; N (1 AMINO 1 OXOPROPAN 2 YL) 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 4 FLUORO 1H INDOLE 2 CARBOXAMIDE; N (2 AMINO 2 OXOETHYL) 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 5 NITRO 1H INDOLE 2 CARBOXAMIDE; N (2 AMINO 2 OXOETHYL) 5 BROMO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 1H INDOLE 2 CARBOXAMIDE; N (2 AMINO 2 OXOETHYL) 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 1H INDOLE 2 CARBOXAMIDE; N (2 AMINO 2 OXOETHYL) 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 4 FLUORO 1H INDOLE 2 CARBOXAMIDE; N (3 AMINO 3 OXOPROPYL) 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 5 NITRO 1H INDOLE 2 CARBOXAMIDE; N (3 AMINO 3 OXOPROPYL) 5 BROMO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 1H INDOLE 2 CARBOXAMIDE; N (3 AMINO 3 OXOPROPYL) 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 1H INDOLE 2 CARBOXAMIDE; N (3 AMINO 3 OXOPROPYL) 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 4 FLUORO 1H INDOLE 2 CARBOXAMIDE; N (4 AMINO 4 OXOBUTAN 3 YL) 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 5 NITRO 1H INDOLE 2 CARBOXAMIDE; N (4 AMINO 4 OXOBUTAN 3 YL) 5 BROMO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 1H INDOLE 2 CARBOXAMIDE; N (4 AMINO 4 OXOBUTAN 3 YL) 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 1H INDOLE 2 CARBOXAMIDE; N (4 AMINO 4 OXOBUTAN 3 YL) 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 4 FLUORO 1H INDOLE 2 CARBOXAMIDE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B4; CYTOSTASIS; CYTOTOXICITY; DRUG BINDING; DRUG CONFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; T LYMPHOCYTE; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

AMINO ACIDS; ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSTATIC AGENTS; DRUG RESISTANCE, VIRAL; ENTEROVIRUS B, HUMAN; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; HYDROPHOBICITY; INDOLES; LYMPHOCYTES; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; PROTEIN BINDING; REVERSE TRANSCRIPTASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; VIRUS REPLICATION;

EID: 64549155260     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801470b     Document Type: Article

References (51)

1. WHO/UNAIDS. 2007AIDS epidemic update.
2. Flexner, C. HIV drug development: the next 25 years. ReV. Drug DiscoVery 2007, 6, 959-966.
3. (a) De Clercq, E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-517.
4. (b) De Clercq, E. Highlights in the development of new antiviral agents. Mini-ReV. Med. Chem. 2002, 2, 163-175.
5. (c) Williams, I. G. Enfuvirtide (Fuzeon): the first fusion inhibitor. Int. J. Clin. Pract. 2003, 57, 890-897.
6. Oversteegen, L.; Shah, M.; Rovini, H. HIV combination products. Nat. ReV. Drug DiscoVery2007, 6, 951-952.
7. (a) Orkin, C.; Stebbing, J.; Nelson, M.; Bower, M.; Johnson, M.; Mandalia, S.; Jones, R.; Moyle, G.; Fisher, M.; Gazzard, B. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy. J. Antimicrob. Chemother. 2005, 55, 246-251.
8. (b) Li, X.; Margolick, J. B.; Connover, C. S.; Badri, S.; Riddler, S. A.; Witt, M. D.; Jacobson, L. P. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J. Acquired Immune Defic. Syndr. 2005, 38, 320-328.
9. Vandamme, A.-M.; Van Vaerenbergh, K.; De Clercq, E. Anti-human immunodeficiency virus drug combination strategies. AntiViral Chem. Chemother. 1998, 9, 187-203.
10. (a) Corbett, J. W.; Rodgers, J. D. Discovery of second generation of quinazoline non-nucleoside reverse transcriptase inhibitors of HIV-1. Prog. Med. Chem. 2002, 40, 63-105.
11. (b) Haslinger, B. A.; Arendt, G. TMC-125 Tibotec. Curr. Opin. InVest. Drugs 2004, 5, 208-213.
12. Haubrich, R.; Gubernick, S.; Yasothan, U.; Kirkpatrick, P. Etravirine. Nat. ReV. Drug DiscoVery 2008, 7, 287-288.
13. (a) Williams, T. A.; Ciccarone, T. M.; Saari, W. S.; Wai, J. S.; Greenlee, W. J.; Balani, S. K., Goldman, M. E.; Theoharides, A. D. Indoles as Inhibitors of HIV Reverse Transcriptase. Patent Application EP 0 530 907 A1, 1992.
14. (b) Williams, T. M.; Ciccarone, T. M.; MacTough, S. C.; Rooney, C. S.; Balani, S. K.; Condra, J. H.; Emini, E. A.; Goldman, M. E.; Greenlee, W. J.; Kauffman, L. R.; O'Brien, J. A.; Sardana, V. V.; Schleif, W. A.; Theoharides, A. D.; Anderson, P. S. 5-Chloro-3-(phenylsulfonyl)indole-2-carboxyamide: a novel nonnucleoside inhibitor of the HIV-1 reverse transcriptase. J. Med. Chem. 1993, 36, 1291-1294.
15. Silvestri, R.; De Martino, G.; La Regina, G.; Artico, M.; Massa, S.; Vargiu, L.; Mura, M.; Loi, A. G.; Marceddu, T.; La Colla, P. Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. J. Med. Chem. 2003, 46, 2482-2493.
16. Silvestri, R.; Artico, M.; De Martino, G.; La Regina, G.; Loddo, R.; La Colla, M.; La Colla, P. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild-type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations. J. Med. Chem. 2004, 47, 3892-3896.
17. Young, S. D.; Amblard, M. C.; Brichter, S. F.; Grey, V. E.; Tran, L. O.; Lumma, W. C., Jr.; Huff, J. R.; Schleif, W. A.; Emini, E. E.; O'Brien, J. A.; Pettibone, D. J. 2-Heterocyclic indole-3-sulfones as inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 1995, 5, 491-496.
18. (a) Ragno, R.; Artico, M.; De Martino, G.; La Regina, G.; Coluccia, A.; Di Pasquali, A.; Silvestri, R. Docking and 3-D QSAR studies on indolyl aryl sulfones (IASs). Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl) carboxyamide and N-(2-hydroxyethyl) carboxyhydrazide derivative. J. Med. Chem. 2005, 48,213-223.
19. (b) De Martino, G.; La Regina, G.; Ragno, R.; Coluccia, A.; Bergamini, A; Ciaprini, C.; Sinistro, A.; Maga, G.; Crespan, E; Artico, M.; Silvestri, R. Indolyl aryl sulfones (IASs) as HIV-1 non-nucleoside reverse transcriptase inhibitors. Synthesis, biological evaluation and binding mode studies of new derivatives at indole- 2-carboxamide. AntiViral Chem. Chemother. 2006, 57, 59-77.
20. Ragno, R.; Coluccia, A.; La Regina, G.; De Martino, G.; Piscitelli, F.; Lavecchia, A.; Novellino, E.; Bergamini, A.; Ciaprini, C.; Sinistro, A.; Maga, G.; Crespan, E.; Artico, M.; Silvestri, R. Design, molecular modeling, synthesis and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.J. Med. Chem.2006, 49, 3172-3184.
21. (a) Corbett, J. W.; Rodgers, J. D. Discovery of second generation of quinazoline non-nucleoside reverse transcriptase inhibitors of HIV-1. Prog. Med. Chem. 2002, 40, 63-105.
22. (b) Corbett, J. W.; Ko, S. S.; Rodger, J. D.; Jeffrey, S.; Bacheler, L. T.; Klabe, R. M.; Diamond, S.; Lai, C.-M.; Rabel, S. R.; Saye, J. A.; Adams, S. P.; Trainor, G. L.; Anderson, P. S.; Erickson-Viitanen, S. K. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1999, 43, 2893-2897.
23. La Regina, G.; Coluccia, A.; Piscitelli, F.; Bergamini, A.; Sinistro, A.; Cavazza, A.; Maga, G.; Samuele, A.; Zanoli, S.; Novellino, E.; Artico, M.; Silvestri, R. Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity. J. Med. Chem. 2007, 50, 5034-5038.
24. Storer, R.; Alexandre, F.-R.; Dousson, C.; Moussa. A. M.; Bridges, E. Enantiomerically Pure Phosphoindoles as HIV Inhibitors. PCT Int. Appl. WO 2008/042240, 2008.
25. Zhao, Z.; Wolkenberg, S. E.; Lu, M.; Munshi, V.; Moyer, G.; Feng, M.; Carella, A. V.; Ecto, L. T.; Gabryelski, L. J.; Lai, M.-T.; Prasad, S. G.; Yan, Y.; McGaughey, G. B.; Miller, M. D.; Lindsley, C. W.; Hartman, G. D.; Vacca, J. P.; Williams, T. M. Novel indole-3- sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs). Bioorg. Med. Chem. Lett. 2008, 18, 554-559.
26. Piscitelli, F.; La Regina, G.; Silvestri, R. An improved synthesis of ethyl 5-chloro-4-fluoro-1H-indole-2-carboxylate. Org. Prep. Proced. Int. 2008, 40, 216-220.
27. Hara, T.; Durell, S. R.; Myers, M. C.; Appella, D. H. Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions. J. Am. Chem. Soc. 2006, 128, 1995-2004.
28. Hsiao, Y.; Hegedus, L. S. Synthesis of optically active imidazolines, azapenams, dioxocyclams, and bis-dioxocyclams. J. Org. Chem. 1997, 62, 3586-3591.
29. Tucker, T. J.; Sisko, J. T.; Tynebor, R. M.; Williams, T. M.; Felock, P. J.; Flynn, J. A.; Lai, M.-T.; Liang, Y.; McGaughey, G.; Liu, M.; Miller, M.; Munshi, M. V.; Perlow-Poehnelt, R.; Prasad, S.; Reid, J. C.; Sanchez, R.; Torrent, M.; Vacca, J. P.; Wan, B.-L.; Yan, Y. Discovery of 3-{5-[(6-amino-1H- pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. J. Med. Chem. 2008, 51, 6503-6511.
30. Janssen, P. A. J.; Lewi, P. J.; Arnold, E.; Daeyaert, F.; deJonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Ludovici, D.; Andries, K.; de Béthune, M.-P.; Pauwels, R.; Das, K.; Clark, A. T., Jr.; Frenkel, Y. V.; Stephen H. Hughes, S. H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffelsb, P. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile (R278474, rilpivirine). J. Med. Chem. 2005, 48, 1901-1909.
31. De Palma, A. M.; Vliegen, I.; De Clercq, E.; Neyts, J. Selective inhibitors of picornavirus replication. Med. Res. ReV. 2008, 823, 884.
32. (a) Beressi, A.; Sunheimer, R. L.; Huish, S.; Kinck, C.; Pincus, M. R. Acute severe rhabdomyolysis in a human immunodeficiency virusseropositive patient associated with rising anti-Coxsackie B viral titers. Ann. Clin. Lab. Sci. 1994, 24, 278-281.
33. (b) Neves, O.; Stein, C. M.; Thomton, C.; Gangaidzo, I.; Thomas, J. E. Rhabdomyolysis associated with immunodeficiency virus (HIV) infection. Cent. Afr. J. Med. 1991, 37, 387-388.
34. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recognit. 1996, 9, 1-5.
35. Korb, O.; Stützle, T.; Exner, T. E. PLANTS: Application of Ant Colony Optimization to Structure-Based Drug Design. In Ant Colony Optimization and Swarm Intelligence, 5th International Workshop, ANTS 2006, Brussels, Belgium, Sep 4-7, 2006; Dorigo, M., Gambardella, L. M., Birattari, M., Martinoli. A., Poli, R., Stützle, T., Eds.; Springer: Berlin, 2006; LNCS 4150, pp 247-258, http://dx.doi.org/ 10.1007/11839088-22.
36. Biosolveit FlexX 2.2; BioSolveIT GmbH An der Ziegelei 75, 53757 Sankt Augustin, Germany. http://www.biosolveit.de/flexx.
37. Molecular Operating Environment (MOE); Chemical Computing Group, Inc. Montreal, Quebec, Canada. www.chemcomp.com.
38. Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
39. Das, K.; Bauman, J. D.; Clark, A. D., Jr.; Frenkel, Y. V.; Lewi, P. J.; Shatkin, A. J.; Hughes, S. H.; Arnold, E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 1466-1471.
40. Ren, J.; Milton, J.; Weaver, K. L.; Short, S. A.; Stuart, D. I.; Stammers, D. K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 2000, 8, 1089-1094.
41. Ren, J.; Nichols, C. E.; Chamberlain, P. P.; Weaver, K. L.; Short, S. A.; Stammers, D. K. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J. Mol. Biol. 2004, 336, 569-578.
42. Ren, J.; Nichols, C. E.; Chamberlain, P. P.; Weaver, K. L.; Short, S. A.; Chan, J. H.; Kleim, J. P.; Stammers, D. K. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases. J. Med. Chem. 2007, 50, 2301-2309.
43. Ren, J.; Nichols, C.; Bird, L.; Chamberlain, P.; Weaver, K.; Short, S.; Stuart, D. I.; Stammers, D. K. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation nonnucleoside inhibitors. J. Mol. Biol. 2001, 312, 795-805.
44. De Clercq, E. Antivirals: current state of art. Future Virol. 2008, 3, 393-405.
45. Surflex, version 2.1; Tripos, Inc., St. Louis, MO 63144.
46. SYBYL 8.0; Tripos Inc., 1699 South Hanley Road, St. Louis, MO 63144. http://www.tripos.com.
47. Zodiac. www.zeden.org.
48. Code "scoring.svl" obtained from SLV exchange Web site. Chemical Computing Group, Inc., Montreal, Canada. http://svl.chemcomp.com.
49. PyMOL; DeLano Scientific LLC, San Carlos, CA. www.pymol.org.
50. Van Nhien, A. N.; Tomassi, C.; Len, C.; Marco-Contelles, J. L.; Balzarini, J.; Pannecouque, C.; De Clercq, E.; Postel, D. First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication. J. Med. Chem. 2005, 48, 4276-4284.
51. Maga, G.; Amacker, M.; Ruel, N.; Hubsher, U.; Spadari, S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 1997, 274, 738-747.